Products for Research Use Only

MIF-1 (TFA)

CAT: 0804-HY-107663A-01Size: 25 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-107663A-01Size:25 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
MIF-1 TFA (Melanostatin), an endogenous brain peptide, is a potent dopamine receptor allosteric modulator. MIF-1 TFA inhibits melanin formation. MIF-1 TFA blocks the effects of opioid receptor activation to modulate the analgesic effects. MIF-1 TFA accesses from the blood to the CNS by directly crossing the blood-brain barrier (BBB) [1][2][3].
CAS Number
35240-69-8
Product Name Alternative
Pro-Leu-Gly-NH2 (TFA) ; Melanostatin (TFA)
UNSPSC
12352209
Hazard Statement
H302, H312, H332
Target
Dopamine Receptor
Type
Peptides
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Cancer-programmed cell death
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/mif-1-tfa.html
Purity
99.34
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(NCC(N)=O)[C@H](CC(C)C)NC([C@@H]1CCCN1)=O.OC(C(F)(F)F)=O
Molecular Formula
C15H25F3N4O5
Molecular Weight
398.38
Precautions
H302, H312, H332
References & Citations
[1]Bocheva A, et, al. Antiopioid properties of the TYR-MIF-1 family. Methods Find Exp Clin Pharmacol. 2004 Nov;26 (9) :673-7.|[2]Valentijn JA, et, al. Melanostatin (NPY) inhibited electrical activity in frog melanotrophs through modulation of K+, Na+ and Ca2+ currents. J Physiol. 1994 Mar 1;475 (2) :185-95.|[3]Saleh MI, et, al. MIF-1 attenuates spiroperidol alteration of striatal dopamine D2 receptor ontogeny. Peptides. 1989 Jan-Feb;10 (1) :35-9.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
Scientific Category
Peptides
Clinical Information
No Development Reported